Találati lista | Tudóstér

001-es BibID:	BIBFORM015838
Első szerző:	Orbach, Hedi
Cím:	Prolactin and Autoimmunity : hyperprolactinemia Correlates with Serositis and Anemia in SLE Patients / Orbach, H., Zandman-Goddard, G., Boaz, M., Agmon-Levin, N., Amital, H., Szekanecz, Z., Szucs, G., Rovensky, J., Kiss, E., Doria, A., Ghirardello, A., Gomez-Arbesu, J., Stojanovich, L., Ingegnoli, F., Meroni, P. L., Rozman, B., Blank, M., Shoenfeld, Y.
Dátum:	2012
ISSN:	1559-0267 (Electronic)
Megjegyzések:	Evidence points to an association of prolactin to autoimmune diseases. We examined the correlation between hyperprolactinemia and disease manifestations and activity in a large patient cohort. Age- and sex-adjusted prolactin concentration was assessed in 256 serum samples from lupus patients utilizing the LIASON prolactin automated immunoassay method (DiaSorin S.p.A, Saluggia, Italy). Disease activity was defined as present if European Consensus Lupus Activity Measurement (ECLAM) > 2 or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 4. Lupus manifestations were grouped by organ involvement, laboratory data, and prescribed medications. Hyperprolactinemia was presented in 46/256 (18%) of the cohort. Hyperprolactinemic patients had significantly more serositis (40% vs. 32.4%, p = 0.03) specifically, pleuritis (33% vs. 17%, p = 0.02), pericarditis (30% vs. 12%, p = 0.002), and peritonitis (15% vs. 0.8%, p = 0.003). Hyperprolactinemic subjects exhibited significantly more anemia (42% vs. 26%, p = 0.02) and marginally more proteinuria (65.5% vs. 46%, p = 0.06). Elevated levels of prolactin were not significantly associated with other clinical manifestations, serology, or therapy. Disease activity scores were not associated with hyperprolactinemia. Hyperprolactinemia in lupus patients is associated with all types of serositis and anemia but not with other clinical, serological therapeutic measures or with disease activity. These results suggest that dopamine agonists may be an optional therapy for lupus patients with hyperprolactinemia.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Clinical Reviews in Allergy and Immunology. - 42 : 2 (2012), p. 189-198. -
További szerzők:	Zandman-Goddard, Gisele Boaz, Mona Agmon-Levin, Nancy Amital, Howard Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Rovensky, Josef Kiss Emese (1960-) (belgyógyász, immunológus) Doria, Andrea Ghirardello, A. Gomez-Arbesu, Jesus Stojanovich, Ljudmila Ingegnoli, Francesca Meroni, Pier Luigi Rozman, Blaz Blank, Marion Shoenfeld, Yehuda
Internet cím:	DOI elektronikus változat Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM001205
035-os BibID:	PMID:17916982
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:	2007
Megjegyzések:	Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban SLE antiphospholipid antibodies thrombotic manifestation APS Follow-up LAC Primary prophylaxis acetylsalicylic acid antithrombocytic agent beta2 glycoprotein 1 antibody cardiolipin antibody coumarin lupus anticoagulant phospholipid antibody adult antiphospholipid syndrome article cerebrovascular accident cohort analysis controlled study data base deep vein thrombosis disease association disease course drug efficacy female follow uphigh risk population history of medicine human international normalized ratio lung embolism major clinical study male medical record prevalence prophylaxis prospective study stroke systemic lupus erythematosus thrombosis transient ischemic attack Adult Antibodies, Antiphospholipid Antibody Specificity Anticoagulants Antiphospholipid Syndrome Aspirin Cohort Studies Female Follow-Up Studies Humans Lupus Erythematosus, Systemic Male Middle Aged Thrombosis Time Factors egyetemen (Magyarországon) készült közlemény
Megjelenés:	Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:	Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon:

001-es BibID:	BIBFORM015927
Első szerző:	Zandman-Goddard, Gisele
Cím:	Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients / Zandman-Goddard, G., Orbach, H., Agmon-Levin, N., Boaz, M., Amital, H., Szekanecz, Z., Szucs, G., Rovensky, J., Kiss, E., Corocher, N., Doria, A., Stojanovich, L., Ingegnoli, F., Meroni, P. L., Rozman, B., Gomez-Arbesu, J., Blank, M., Shoenfeld, Y.
Dátum:	2013
ISSN:	1559-0267 (Electronic)
Megjegyzések:	Ferritin may play a direct role on the immune system. We sought to determine if elevated levels of ferritin in lupus patients correlate with disease activity and organ involvement in a large cohort. Ferritin levels (gender and age adjusted) were assessed in 274 lupus serum samples utilizing the LIASON Ferritin automated immunoassay method. Significant disease activity was determined if European Consensus Lupus Activity Index (ECLAM) > 2 or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) > 4. Utilizing an EXCEL database, we compared elevated ferritin levels to manifestations grouped by organ involvement, serology, and previous therapy. The patients were predominantly female (89%), median age was 37 years old, and disease duration was 10.6 +/- 7.7 years. Hyperferritinemia was found in 18.6% of SLE patients. Compared to subjects with normal ferritin levels, a significantly greater proportion of patients with hyperferritinemia had thrombocytopenia (15.4% vs. 33.3%, p = 0.003) and lupus anticoagulant (11.3% vs. 29.0%, p = 0.01). Additionally, compared to normoferritinemic subjects, hyperferritinemic subjects had significantly higher total aCL (99.7 +/- 369 vs. 30.9 +/- 17.3 GPI, p = 0.02) and aCL IgM antibody levels (75.3 +/- 357.4 vs. 9.3 +/- 10.3 GPI, p = 0.02), and marginally lower aCL IgG antibody levels (9.2 +/- 4.9 vs. 9.7 +/- 3.9 GPI, p = 0.096). While the ECLAM score significantly correlated with hyperferritinemia (p = 0.04), the SLEDAI score was marginally associated with hyperferritinemia (p = 0.1). Serositis was marginally associated with hyperferritinemia, but not with other manifestations. An association with serologic APS was encountered. Hyperferritinemia was associated with thrombocytopenia, lupus anticoagulant, and anti-cardiolipin antibodies suggest that it may be an early marker for secondary antiphospholipid syndrome in SLE patients.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Clinical Reviews in Allergy and Immunology. - 44 : 1 (2013), p. 23-30. -
További szerzők:	Orbach, Hedi Agmon-Levin, Nancy Boaz, Mona Amital, Howard Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Rovensky, Josef Kiss Emese (1960-) (belgyógyász, immunológus) Corocher, Nadia Doria, Andrea Stojanovich, Ljudmila Ingegnoli, Francesca Meroni, Pier Luigi Rozman, Blaz Gomez-Arbesu, Jesus Blank, Miri Shoenfeld, Yehuda
Internet cím:	DOI elektronikus változat Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: